Clinical Trial Update: Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating cediranib combined with cisplatin and capecitabine or S-1 in Japanese patients with gastric cancer; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Capecitabine (capecitabine)
• Cediranib (Cediranib)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: AstraZeneca | Conditions: Gastric Cancer | Phase 1 | Status: COMPLETED